Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

Grape seed extract—a dietary supplement made from the seeds of wine grapes—has been investigated to see if it can help reduce ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...